Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01874392 · ClinicalTrials.gov registry record · NA
Feasibility Study Using Zone-MPC Controller, HMS and Technosphere® Insulin Inhalation System From MannnKind Corp
A NA study of Type 1 Diabetes Mellitus, sponsored by Sansum Diabetes Research Institute.
- Completed
- Registry status
- NA
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT01874392 is a NA study of Type 1 Diabetes Mellitus that has completed, run by Sansum Diabetes Research Institute. The registered enrollment target is 9 participants, below the 140-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01874392, a NA study of Type 1 Diabetes Mellitus, has completed, sponsored by Sansum Diabetes Research Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial is a feasibility study to assess the performance of an Artificial Pancreas (AP) device using the Artificial Pancreas System (APS©) platform for subjects with type 1 diabetes using rapid-acting insulin as well as preprandial inhaled insulin (Technosphere® Insulin Inhalation System by MannKind Corporation). The goal of this proposed study is to explore the feasibility of using multiple insulin delivery routes in order to mimic the physiology of both first- and second-phase insulin secretion. The intent is to exploit the rapid action achieved by inhaled insulin to compensate for part of the meals and utilize the conventional subcutaneous route for management of basal insulin and as second-phase meal-related insulin.
Conditions Studied
Interventions
- DRUG Investigational inhaled insulin (Technosphere)
- DEVICE Artificial Pancreas (AP) device (APS©)
Study Locations (1)
California
- Sansum Diabetes Research Institute - Santa Barbara
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2012-10 |
| Est. Completion | 2013-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01874392
The ClinicalTrials.gov registry entry for NCT01874392 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 140-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (94% lower). The listed sponsor is Sansum Diabetes Research Institute, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Investigational inhaled insulin (Technosphere) is the first listed.
NCT01874392 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01874392 about?
NCT01874392 is a clinical study titled "Feasibility Study Using Zone-MPC Controller, HMS and Technosphere® Insulin Inhalation System From MannnKind Corp". This clinical trial is a feasibility study to assess the performance of an Artificial Pancreas (AP) device using the Artificial Pancreas System (APS©) platform for subjects with type 1 diabetes using rapid-acting insulin as well as preprandial inhaled insulin (Technosphere® Insulin Inhalation System...
What is the current status of trial NCT01874392?
This trial is currently completed. It is a NA study. The enrollment target is 9 participants. The study started on 2012-10. Estimated completion is 2013-06.
What conditions does trial NCT01874392 study?
This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.
What interventions are being tested in trial NCT01874392?
The interventions under investigation include: Investigational inhaled insulin (Technosphere) (DRUG), Artificial Pancreas (AP) device (APS©) (DEVICE).
Who is sponsoring clinical trial NCT01874392?
This trial is sponsored by Sansum Diabetes Research Institute, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01874392 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Accuracy and Precision of the Continuous Glucose Monitoring System 'CareSens Air 3' in Adult Patients With T1DM
RECRUITING · NA
-
Implementing the Spotlight AQ Platform in Adolescent/ Young Adult (16-25 Years Old) Type 1 Diabetics (T1D)
RECRUITING · NA
-
A Hybrid Effectiveness-implementation Trial to Reduce Diabetes Distress in Teenagers
RECRUITING · NA
-
PACTAID App in Adults With Type 1 Diabetes to Help Manage Exercise
RECRUITING · NA
-
GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes
RECRUITING · NA
-
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.